Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Cytokinetics Inc.CYTK · healthcare | |
|---|---|
| Grade |  Bsecond fifth of 371 graded peers; percentile 29.5, sampling error 2.5 points; lower is stronger |
| Rank | 110 of 371 |
| Profitability | A/Bpercentile 22.5 |
| Solvency | Cpercentile 54.3 |
| Growth and financing | Cpercentile 49.4 |
| Reliability | 0.91 AUCfailure model, filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| Peer failure rate | 1.01% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $591M to $2.67B assetstotal assets $1.4B[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | short runway |
| Inputs computable | 8 of 14 |
| Graded from | filings received through Feb 26, 2026225 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $62.002026-10-08; market equity $8.6B; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Feb 26, 2026; the document on sec.gov.
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Our first commercial product is MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, and 20 mg tablets, which the FDA approved in December 2025. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 22.5 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31 | |||||||
| Accruals ratio | (19.5%) | [1,4-6] | (6.6%) | 22.5 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 54.3 | |||||||
| Twelve-month failure probability | 0.09% | 0.07% | 55.5 | 248 | 2026-06-30 | ||
| Altman Z double-prime | (7.91) | [1,7-12] | (0.31) | 58.3 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | (13.43x) | [10,13] | (4.51x) | 62.5 | 81 | 2025-12-31 | |
| Current ratio | 4.53x | [7-8] | 2.96x | 40.8 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 49.4 | |||||||
| Revenue growth, three-year compound | (2.4%) | [2,14-16] | 10.0% | 76.6 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | 12.0% | [1,6,17-18] | 2.1% | 29.2 | 704 | 2025-12-31 | |
| Net share issuance, one year | 4.0% | [19-20] | 2.5% | 42.3 | 634 | 2026-02-23 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite -0.191; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 105 | Agios Pharmaceuticals, Inc. (AGIO) Agios Pharmaceuticals, Inc. (AGIO) Bsecond fifth; percentile 28.1 Nasdaq · Pharmaceutical Preparations market equity $1.9B; last close $31.92 Warnings: short runway; 8 of 14 inputs | 28.1 | B | short runway |
| 106 | Myriad Genetics Inc. (MYGN) Myriad Genetics Inc. (MYGN) Bsecond fifth; percentile 28.4 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $401.7M; last close $4.17 Warnings: fortress balance sheet; 7 of 14 inputs | 28.4 | B | fortress balance sheet |
| 107 | DocGo Inc. (DCGO) DocGo Inc. (DCGO) Bsecond fifth; percentile 28.6 Nasdaq · Services-Health Services market equity $33.5M; last close $0.34 Warnings: late filer, fortress balance sheet; 7 of 14 inputs | 28.6 | B | late filer, fortress balance sheet |
| 108 | Healthcare Services Group Inc. (HCSG) Healthcare Services Group Inc. (HCSG) Bsecond fifth; percentile 28.9 Nasdaq · Services-Nursing & Personal Care Facilities market equity $1.4B; last close $20.66 No active warnings; 7 of 14 inputs | 28.9 | B | |
| 109 | Staar Surgical Co. (STAA) Staar Surgical Co. (STAA) Bsecond fifth; percentile 29.2 Nasdaq · Ophthalmic Goods market equity $1.1B; last close $22.38 No active warnings; 9 of 14 inputs | 29.2 | B | |
| 110 | Cytokinetics Inc. (CYTK) Cytokinetics Inc. (CYTK) Bsecond fifth; percentile 29.5 Nasdaq · Pharmaceutical Preparations market equity $8.6B; last close $62.00 Warnings: short runway; 8 of 14 inputs | 29.5 | B | short runway |
| 111 | Steris plc (STE) Steris plc (STE) Bsecond fifth; percentile 29.7 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $20.5B; last close $210.74 No active warnings; 10 of 14 inputs | 29.7 | B | |
| 112 | Cadre Holdings, Inc. (CDRE) Cadre Holdings, Inc. (CDRE) Bsecond fifth; percentile 30.0 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $1.1B; last close $24.80 No active warnings; 10 of 14 inputs | 30.0 | B | |
| 113 | MSA Safety Inc. (MSA) MSA Safety Inc. (MSA) Bsecond fifth; percentile 30.3 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies last close $177.94 No active warnings; 11 of 14 inputs | 30.3 | B | |
| 114 | BioNexus Gene Lab Corp. (BGLC) BioNexus Gene Lab Corp. (BGLC) Bsecond fifth; percentile 30.5 Nasdaq · Services-Medical Laboratories market equity $3.7M; last close $1.24 Warnings: dilution, late filer; 8 of 14 inputs | 30.5 | B | dilution, late filer |
| 115 | Arcutis Biotherapeutics, Inc. (ARQT) Arcutis Biotherapeutics, Inc. (ARQT) Bsecond fifth; percentile 30.8 Nasdaq · Pharmaceutical Preparations market equity $3.1B; last close $24.49 No active warnings; 7 of 14 inputs | 30.8 | B |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | B | 33.8 | 2204 |
| sector peers, equal sleeves (the grade) | B | 29.5 | 371 |
| same exchange, equal sleeves | B | 35.6 | 1219 |
| sector peers, equal inputs | C | 51.9 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 29.0% | 8.0% | 64 | hotter than 64 of 100 peers |
| Distance from 52-week high | (28.9%) | (31.4%) | 54 | closer to its high than 54 of 100 peers |
| EBIT to enterprise value | (6.5%) | (1.5%) | 37 | pricier than 63 of 100 peers |
| Free cash flow yield | (6.2%) | (1.0%) | 38 | pricier than 62 of 100 peers |
| Book value to price | (0.02) | 0.28 | 10 | pricier than 90 of 100 peers |
| Sales to price | 0.01 | 0.31 | 6 | pricier than 94 of 100 peers |
| Composite equity issuance, five years | 67.0% | 20.3% | 69 | more equity-funded than 69 of 100 peers |
| Relative strength against the sector, log excess return | 0.04 | (0.14) | 64 | ahead of 64 of 100 peers |
Inputs: market equity $8.6B; EBIT -$612.3M; free cash flow -$534.8M; book equity -$173.5M; sales $88.0M; debt $1.0B; cash $255.3M[21].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (56.0%) | ✗ fail[4,6] |
| Operating cash flow above zero | -$510.0M | ✗ fail[5] |
| Return on assets improved | 15.5 pts | ✓ pass[4,6,17,22] |
| Operating cash flow exceeds net income | $274.9M | ✓ pass[4-5] |
| Long-term leverage fell | 9.1 pts | ✗ fail[1,6,17,23-24] |
| Current ratio improved | (163.7 pts) | ✗ fail[7-8,25-26] |
| No new shares issued | 4.0% | ✗ fail[19-20] |
| Gross margin improved | n/a | |
| Asset turnover improved | 4.0 pts | ✓ pass[2,6,14,17] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $255.3M[3] |
| Operating cash flow, four quarters | -$555.5M[3,5,27-30] |
| Months of runway | 5.5 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 64 |
| 10-Q received Aug 6, 2026 | |
| Median daily dollar volume | $130.1M |
| 63 sessions | |
| Days since newest grade input | 225 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $1.4B | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $88.0M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $255.3M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 4 | net income | us-gaap:NetIncomeLoss | -$785.0M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$510.0M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 6 | assets | us-gaap:Assets | $1.4B | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 7 | current assets | us-gaap:AssetsCurrent | $917.0M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $202.5M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$3.5B | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$612.3M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 11 | book equity | us-gaap:StockholdersEquity | -$659.6M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 12 | liabilities | us-gaap:Liabilities | $2.1B | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 13 | interest expense | us-gaap:InterestExpense | $45.6M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $18.5M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $7.5M | 2023-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $94.6M | 2022-12-31 | 2025-02-27 | 10-K | filing · viewer · series |
| 17 | assets | us-gaap:Assets | $824.3M | 2023-12-31 | 2025-02-27 | 10-K | filing · viewer · series |
| 18 | assets | us-gaap:Assets | $1.0B | 2022-12-31 | 2024-02-28 | 10-K | filing · viewer · series |
| 19 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 123,162,807 | 2026-02-23 | 2026-02-26 | 10-K | filing · viewer · series |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 118,410,689 | 2025-02-26 | 2025-02-27 | 10-K | filing · viewer · series |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 139,023,418 | 2026-08-04 | 2026-08-06 | 10-Q | filing · viewer · series |
| 22 | net income | us-gaap:NetIncomeLoss | -$589.5M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 23 | long term debt | us-gaap:LongTermDebtNoncurrent | $246.4M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 24 | long term debt | us-gaap:LongTermDebtNoncurrent | $93.2M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 25 | current assets | us-gaap:AssetsCurrent | $1.1B | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 26 | current liabilities | us-gaap:LiabilitiesCurrent | $179.7M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$305.3M | 2026-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$145.5M | 2026-03-31 | 2026-05-05 | 10-Q | filing · viewer · series |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$367.4M | 2025-09-30 | 2025-11-05 | 10-Q | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$259.9M | 2025-06-30 | 2026-08-06 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 29.5 is 9.5 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
